Zaprinast as a novel therapy arterial hypertension : mechanisms of action and cannabinoids as anti-typertensives
Most pulmonary arterial hypertension therapies are centred around the use of anticoagulants, which risk haemorrhaging, and anti-hypertensive drugs, which risk systemic hypotension. The PDE5 inhibitor, zaprinast, is believed to have vasorelaxant properties specific to the pulmonary arterial bed. In t...
| Main Author: | |
|---|---|
| Published: |
University of Strathclyde
2009
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.502277 |